Synairgen
('Synairgen' or the 'Company')
First Patient Dosed in the Global Phase 2 INVENT Clinical Study
Southampton, UK. 8 December 2025: Synairgen today announced that the first participant has been dosed in the global phase 2 INVENT clinical study, which is designed to evaluate the efficacy and safety of SNG001 (inhaled interferon-beta) in mechanically-ventilated patients infected with a range of respiratory viruses. SNG001 is a broadly-acting anti-viral which is targeted to the lungs using a specific nebuliser technology enabled by the Company's partnership with Aerogen.
"Dosing the first patient in this key phase 2 study marks an important milestone and an important step in the development of an effective therapeutic in this underserved population, which experiences a very high rate of mortality and imposes significant clinical and economic burden on the health care systems" said Dr Marcin Mankowski, Chief Medical Officer and Head of Scientific Affairs at Synairgen.
"I am delighted that we have recruited our first patient into this highly important clinical trial aimed at improving outcomes for patients with severe respiratory viral infections in the intensive care unit. This study represents an exciting step towards providing innovative therapeutics, with the potential to save lives of patients with severe viral pneumonia" said Prof. Dushianthan Ahilanadan, Intensive Care and Respiratory Consultant at University Hospital Southampton and the Chief Investigator for the INVENT study.
INVENT is a large clinical study which is being progressed in intensive care units of specialised clinical centres in US, UK and selected European countries. It follows a randomised, placebo-controlled, double-blind design and aims to enrol 550 patients, with a protocol-defined interim analysis scheduled during 2026. The primary endpoint is 28-day all-cause mortality, whilst secondary endpoints include duration of mechanical ventilation and of ICU stay, as well as viral load in lung-derived samples.
Joseph Colliver, Synairgen's CEO commented "We are very grateful for all involved at the UK clinical centre where the first patient was dosed, and to all colleagues and partners involved in launching this global study. We look forward to reporting further progress as we seek to push forward this novel and potentially ground-breaking lung-targeted therapeutic, given its significant potential clinical impact and commercial prospects"
Joseph Colliver
Chief Executive Officer
For further enquiries, please contact:
Synairgen Limited
+ 44 (0)23 8051 2800
info@synairgen.com
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on the development of SNG001 (inhaled interferon beta) as potentially the first broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.
Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.
For more information about Synairgen, please see www.synairgen.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
